Advertisement
Silverback Therapeutics I... (SBTX)
Silverback Therapeutics Statistics
Share Statistics
Silverback Therapeutics has 93.77M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 93.77M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.64M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Silverback Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Silverback Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-376.09K |
| Employee Count | 90 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -834K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0, so Silverback Therapeutics's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 5.39 |
| 200-Day Moving Average | 4.38 |
| Relative Strength Index (RSI) | 53.52 |
| Average Volume (20 Days) | 171.41K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -35.52M |
| Net Income | -33.85M |
| EBITDA | -35.52M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.85 |
Balance Sheet
The company has 210.52M in cash and 481K in debt, giving a net cash position of 210.04M.
| Cash & Cash Equivalents | 210.52M |
| Total Debt | 481K |
| Net Cash | 210.04M |
| Retained Earnings | -76.94M |
| Total Assets | 248.56M |
| Working Capital | 233.29M |
Cash Flow
In the last 12 months, operating cash flow was -59.27M and capital expenditures -175K, giving a free cash flow of -59.44M.
| Operating Cash Flow | -59.27M |
| Capital Expenditures | -175K |
| Free Cash Flow | -59.44M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SBTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SBTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 29.31 |
| Piotroski F-Score | 1 |